Early identification using the referral system prolonged the time to onset for hepatic encephalopathy after diagnosing severe acute liver injury.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 10 2020
14 10 2020
Historique:
received:
24
04
2020
accepted:
01
10
2020
entrez:
15
10
2020
pubmed:
16
10
2020
medline:
13
3
2021
Statut:
epublish
Résumé
In 2004, we implemented a referral system for patients with acute liver injury (ALI) based on an established formula that estimates the risk of progression to acute live failure (ALF); however, the benefits of the system for patients with severe acute liver injury (SLI) remain unclear. We have evaluated the clinical significance of the referral system for SLI patients. Patients with ALI/SLI who were consecutively and prospectively listed on the system between 2004 and 2018 were analyzed. Of the 371 ALI/SLI/ALF patients on the system, 124 satisfied the criteria for SLI; 34 of these 124 progressed to SLI after registration. Multivariate analysis using age, sex, AST, ALT, creatinine, total bilirubin, prothrombin, presence of hepatic encephalopathy (HE), and SLI at registration revealed that HE was associated with high mortality. Among the 23 patients who developed HE, five who progressed to SLI after registration showed an increased time to HE development compared with patients who had SLI at the time of registration. However, there was no significant difference in survival time after HE development. We concluded that early identification of SLI patients using the referral system increased the time from SLI diagnosis to HE development.
Identifiants
pubmed: 33057105
doi: 10.1038/s41598-020-74466-2
pii: 10.1038/s41598-020-74466-2
pmc: PMC7560720
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17280Références
Hepatol Res. 2019 Feb;49(2):224-231
pubmed: 30277289
Cytokine. 2016 Oct;86:21-28
pubmed: 27442007
Pharmacoepidemiol Drug Saf. 2006 Jun;15(6):398-405
pubmed: 16294364
Hepatol Res. 2016 Mar;46(5):459-67
pubmed: 26369398
Prog Liver Dis. 1970;3:282-98
pubmed: 4908702
Best Pract Res Clin Gastroenterol. 2012 Feb;26(1):27-33
pubmed: 22482523
J Viral Hepat. 2004 Mar;11(2):97-107
pubmed: 14996343
J Clin Gastroenterol. 2019 Feb;53(2):89-101
pubmed: 30575637
J Gastroenterol Hepatol. 2018 Jan;33(1):277-282
pubmed: 28488376
Hepatol Commun. 2017 Mar 27;1(3):215-229
pubmed: 29404455
Dig Dis Sci. 2020 Mar 3;:
pubmed: 32125573
Nat Rev Gastroenterol Hepatol. 2013 Dec;10(12):746-51
pubmed: 24100300
J Hepatol. 2009 Dec;51(6):1021-9
pubmed: 19864034
Hepatol Res. 2019 Nov;49(11):1286-1293
pubmed: 31251432
Hepatol Res. 2018 Jul;48(8):608-621
pubmed: 29722107
J Gastroenterol. 2017 Aug;52(8):977-985
pubmed: 28078470
Am J Gastroenterol. 2017 Sep;112(9):1389-1396
pubmed: 28440304
Dig Dis Sci. 2020 Mar 17;:
pubmed: 32185661
N Engl J Med. 2013 Dec 26;369(26):2525-34
pubmed: 24369077
Am J Transplant. 2015 Jan;15 Suppl 2:1-28
pubmed: 25626341
J Gastroenterol. 2018 Jun;53(6):752-769
pubmed: 29030713
Liver Transpl. 2006 Dec;12(12):1776-81
pubmed: 17133565
Ann Intern Med. 2002 Dec 17;137(12):947-54
pubmed: 12484709
Hepatology. 2000 Apr;31(4):864-71
pubmed: 10733541
Dig Dis Sci. 2019 May;64(5):1346-1355
pubmed: 30519849
Dig Liver Dis. 2017 Oct;49(10):1139-1145
pubmed: 28663066
Hepatol Res. 2020 Sep 18;:
pubmed: 32949102
Hepatol Res. 2015 Oct;45(10):E12-20
pubmed: 25376981